These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 17382266)

  • 1. Nuclear imaging of neuroendocrine tumours.
    Sundin A; Garske U; Orlefors H
    Best Pract Res Clin Endocrinol Metab; 2007 Mar; 21(1):69-85. PubMed ID: 17382266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PET in the diagnosis of neuroendocrine tumors.
    Sundin A; Eriksson B; Bergström M; Långström B; Oberg K; Orlefors H
    Ann N Y Acad Sci; 2004 Apr; 1014():246-57. PubMed ID: 15153441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved staging of patients with carcinoid and islet cell tumors with 18F-dihydroxy-phenyl-alanine and 11C-5-hydroxy-tryptophan positron emission tomography.
    Koopmans KP; Neels OC; Kema IP; Elsinga PH; Sluiter WJ; Vanghillewe K; Brouwers AH; Jager PL; de Vries EG
    J Clin Oncol; 2008 Mar; 26(9):1489-95. PubMed ID: 18349401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Whole-body (11)C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography.
    Orlefors H; Sundin A; Garske U; Juhlin C; Oberg K; Skogseid B; Langstrom B; Bergstrom M; Eriksson B
    J Clin Endocrinol Metab; 2005 Jun; 90(6):3392-400. PubMed ID: 15755858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional imaging of neuroendocrine tumors: a head-to-head comparison of somatostatin receptor scintigraphy, 123I-MIBG scintigraphy, and 18F-FDG PET.
    Binderup T; Knigge U; Loft A; Mortensen J; Pfeifer A; Federspiel B; Hansen CP; Højgaard L; Kjaer A
    J Nucl Med; 2010 May; 51(5):704-12. PubMed ID: 20395333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nuclear imaging of neuroendocrine tumors with unknown primary: why, when and how?
    Santhanam P; Chandramahanti S; Kroiss A; Yu R; Ruszniewski P; Kumar R; Taïeb D
    Eur J Nucl Med Mol Imaging; 2015 Jun; 42(7):1144-55. PubMed ID: 25771906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nuclear medicine in the detection, staging and treatment of gastrointestinal carcinoid tumours.
    Oberg K; Eriksson B
    Best Pract Res Clin Endocrinol Metab; 2005 Jun; 19(2):265-76. PubMed ID: 15763700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours.
    Teunissen JJ; Kwekkeboom DJ; Valkema R; Krenning EP
    Endocr Relat Cancer; 2011 Oct; 18 Suppl 1():S27-51. PubMed ID: 22005114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nuclear medicine imaging of neuroendocrine tumours.
    Bombardieri E; Maccauro M; De Deckere E; Savelli G; Chiti A
    Ann Oncol; 2001; 12 Suppl 2():S51-61. PubMed ID: 11762353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gastroenteropancreatic neuroendocrine tumours (GEP-NET) - Imaging and staging.
    Baumann T; Rottenburger C; Nicolas G; Wild D
    Best Pract Res Clin Endocrinol Metab; 2016 Jan; 30(1):45-57. PubMed ID: 26971843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of cross-sectional and molecular imaging studies in the localization of gastroenteropancreatic neuroendocrine tumors.
    Toumpanakis C; Kim MK; Rinke A; Bergestuen DS; Thirlwell C; Khan MS; Salazar R; Oberg K
    Neuroendocrinology; 2014; 99(2):63-74. PubMed ID: 24458014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imaging of advanced neuroendocrine tumors with (18)F-FDOPA PET.
    Becherer A; Szabó M; Karanikas G; Wunderbaldinger P; Angelberger P; Raderer M; Kurtaran A; Dudczak R; Kletter K
    J Nucl Med; 2004 Jul; 45(7):1161-7. PubMed ID: 15235062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imaging of neuroendocrine tumors.
    Rufini V; Calcagni ML; Baum RP
    Semin Nucl Med; 2006 Jul; 36(3):228-47. PubMed ID: 16762613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 6-[F-18]fluoro-L-DOPA positron emission tomography in the imaging of Merkel cell carcinoma: preliminary report of three cases with 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography or pentetreotide-(111In) SPECT data.
    Talbot JN; Kerrou K; Missoum F; Grahek D; Aide N; Lumbroso J; Montravers F
    Mol Imaging Biol; 2005; 7(4):257-61. PubMed ID: 16082495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Staging of carcinoid tumours with 18F-DOPA PET: a prospective, diagnostic accuracy study.
    Koopmans KP; de Vries EG; Kema IP; Elsinga PH; Neels OC; Sluiter WJ; van der Horst-Schrivers AN; Jager PL
    Lancet Oncol; 2006 Sep; 7(9):728-34. PubMed ID: 16945767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of (18) F-FDOPA PET/CT imaging in endocrinology.
    Santhanam P; Taïeb D
    Clin Endocrinol (Oxf); 2014 Dec; 81(6):789-98. PubMed ID: 25056984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nuclear Medicine Imaging of Neuroendocrine Tumors.
    Brabander T; Kwekkeboom DJ; Feelders RA; Brouwers AH; Teunissen JJ
    Front Horm Res; 2015; 44():73-87. PubMed ID: 26303705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of positron emission tomography (PET) in diagnostics of gastroenteropancreatic neuroendocrine tumours (GEP NET).
    Junik R; Drobik P; Małkowski B; Kobus-Błachnio K
    Adv Med Sci; 2006; 51():66-8. PubMed ID: 17357280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contemporary nuclear medicine imaging of neuroendocrine tumours.
    Wong KK; Waterfield RT; Marzola MC; Scarsbrook AF; Chowdhury FU; Gross MD; Rubello D
    Clin Radiol; 2012 Nov; 67(11):1035-50. PubMed ID: 22633086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of molecular targeted agents for the diagnosis, staging and therapy of neuroendocrine malignancy.
    Hicks RJ
    Cancer Imaging; 2010 Oct; 10 Spec no A(1A):S83-91. PubMed ID: 20880795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.